In English | En español
Questions About Cancer? 1-800-4-CANCER

Clinical Trials (PDQ®)

Page Options

  • Print This Page
  • Email This Document
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
LiveHelp online chat

Clinical Trials (PDQ®)

Standard Versus Intensity-Modulated Pelvic Radiation Therapy in Treating Patients With Endometrial or Cervical Cancer

Basic Trial Information
Trial Description
     Summary
     Further Trial Information
     Eligibility Criteria
Trial Contact Information

Basic Trial Information

PhaseTypeStatusAgeSponsorProtocol IDs
Phase IIIBiomarker/Laboratory analysis, Supportive care, TreatmentActive18 and overNCI, OtherRTOG 1203
CDR0000738944, NCI-2012-02001, NCT01672892

Trial Description

Summary

RATIONALE: Radiation therapy uses high-energy x-rays and other types of radiation to kill tumor cells. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue.

PURPOSE: This randomized phase III trial is studying two different methods of radiation and their side effects and comparing how well they work in treating endometrial and cervical cancer after surgery.

Further Study Information

OBJECTIVES:

Primary

  • To determine if pelvic intensity-modulated radiation therapy (IMRT) reduces acute gastrointestinal toxicity in the 5th week (after 23-25 fractions) of pelvic radiation as measured with the expanded prostate cancer index composite (EPIC) instrument.

Secondary

  • To determine if grade 2+ gastrointestinal toxicity (Common Terminology Criteria for Adverse Events version 4.0 [CTCAE v. 4.0]) is reduced with IMRT compared to conventional whole-pelvis radiation therapy (WPRT).
  • To determine if grade 2+ hematologic toxicity (CTCAE v. 4.0) is reduced with IMRT compared to conventional WPRT.
  • To determine if urinary toxicity is reduced with IMRT using the EPIC urinary domain.
  • To validate EPIC bowel and urinary domains in women undergoing either IMRT pelvic radiation treatment or four-field pelvic radiation treatment for endometrial or cervical cancer.
  • To assess the impact of pelvic IMRT on quality of life using the Functional Assessment of Cancer Therapy-General (FACT-G) with cervix subscale.
  • To determine if there is any difference in local-regional control, disease-free survival, and overall survival between patients treated with IMRT as compared to conventional WPRT.
  • To perform a health-utilities analysis to measure the financial impact of pelvic IMRT via the EQ-5D instrument.
  • To identify molecular predictors of radiation toxicity and novel circulating cancer biomarkers.

OUTLINE: This is a multicenter study. Patients are stratified according to type of cancer (endometrial vs cervical), chemotherapy (none vs 5 courses of weekly cisplatin at 40 mg/m²), and radiation dose (45 Gy vs 50.4 Gy). Patients are randomized to 1 of 2 treatment arms.

  • Arm I: Patients undergo standard (3-dimensional) radiation therapy 5 days a week for up to 5-6 weeks.
  • Arm II: Patients undergo intensity-modulated radiation therapy (IMRT) 5 days a week for up to 5-6 weeks.

Some patients receive cisplatin IV over 1 hour on day 1. Treatment continues weekly for 5 weeks, concurrently with radiation therapy, in the absence of unacceptable toxicity or disease progression.

Tissue and blood samples may be collected for biomarker and correlative analysis.

Quality of life may be assessed by questionnaires (including the Expanded Prostate Cancer Index Composite [EPIC], the Functional Assessment of Cancer Therapy-General [FACT-G, Version 4], the EQ-5D, and the Common Toxicity Criteria Adverse Events - Patient-Reported Outcome [PRO-CTCAE]) instruments at baseline and periodically during and after study therapy.

After completion of study therapy, patients are followed every 6 months for the first 2 years and then annually for 5 years.

Eligibility Criteria

DISEASE CHARACTERISTICS:

  • Pathologically proven diagnosis of endometrial or cervical cancer within 90 days of registration
  • Patients must have undergone a hysterectomy (total abdominal hysterectomy, vaginal hysterectomy or radical hysterectomy, or total laparoscopic hysterectomy) for carcinoma of the cervix or endometrium within 49 days prior to registration
  • Performance of a bilateral salpingo-oophorectomy will be at the treating surgeon's discretion
  • No positive or close (< 3 mm) resection margins
  • Appropriate stage for protocol entry, including no distant metastases, based upon the following minimum diagnostic workup:
  • History/physical examination within 45 days prior to registration
  • Computed tomography (CT), magnetic resonance imaging (MRI), or positron emission tomography (PET)-CT including the abdomen and pelvis should be performed for initial radiological staging (performed pre- or post-surgery within 90 days prior to registration)
  • Imaging performed postoperatively should show no evidence of residual disease
  • Any evidence of malignancy identified on preoperative imaging should have been completely resected surgically prior to protocol treatment
  • Chest x-ray or chest CT must be performed within 90 days prior to registration (unless a PET-CT has been performed)
  • Endometrial cancer:
  • Patients with the following histologic features are eligible for pelvic radiation therapy without weekly cisplatin:
  • Less than 50% myometrial invasion, grade 3 adenocarcinoma without uterine serous carcinoma (USC), or clear cell histology
  • At least 50% myometrial invasion, grade 1-2 adenocarcinoma without USC, or clear cell histology
  • Patients with the following histologic features may be treated with pelvic radiation with or without weekly cisplatin (the decision to add weekly cisplatin for these patients is at the treating physician's discretion):
  • At least 50% myometrial invasion, grade 3 including USC and clear cell carcinoma
  • International Federation of Gynecology and Obstetrics (FIGO) 2009 stage II endometrial cancer of any grade including USC and clear cell carcinoma
  • FIGO 2009 stage IIIC1 (pelvic lymph node positive only, para-aortic nodes sampled and negative) including USC and clear cell carcinoma
  • Cervical cancer:
  • Patients with the following pathology findings may be treated with pelvic radiation with or without weekly cisplatin at the treating physician's discretion:
  • Patients with intermediate-risk features including two of the following histologic findings after radical hysterectomy: 1/3 or more stromal invasion, lymph-vascular space invasion or large clinical tumor diameter (> 4 cm)
  • Patients with cervical cancer treated with a simple hysterectomy with negative margins
  • Patients with any of the following criteria following radical hysterectomy are eligible for this study and must receive weekly cisplatin:
  • Positive resected pelvic nodes (para-aortic nodes sampled and negative)
  • Microscopic parametrial invasion with negative margins
  • No patients with para-aortic nodal disease or who require extended-field radiotherapy beyond the pelvis
  • No patients with histology consisting of endometrial stromal sarcoma, leiomyosarcoma, malignant mixed mullerian tumor (MMMT), or carcinosarcoma
  • No evidence of metastatic disease outside of the pelvis

PATIENT CHARACTERISTICS:

  • Zubrod performance status 0-2
  • Absolute neutrophil count (ANC) ≥ 1,500 cells/mm³
  • Platelets ≥ 100,000 cells/mm³
  • Hemoglobin (Hgb) ≥ 8.0 g/dL (the use of transfusion or other intervention to achieve Hgb ≥ 8.0 g/dL is acceptable)
  • For patients receiving chemotherapy:
  • Within 14 days prior to registration, serum creatinine ≤ 1.5 mg/dL AND calculated creatinine clearance ≥ 50 mL/min
  • Aspartate aminotransferase (AST) ≤ 2 times upper limit of normal (ULN)
  • Bilirubin ≤ 2 times ULN
  • Alkaline phosphatase, magnesium, blood urea nitrogen (BUN), and electrolytes must be obtained and recorded
  • Fertile patients must use effective contraception
  • Not pregnant and/or breastfeeding
  • Willing and able to complete the bowel and urinary domains of the expanded prostate cancer index composite (EPIC) instrument prior to registration
  • No patients who exceed the weight/size limits of the treatment table or CT scanner
  • No mental status changes or bladder control problems that make the patient unable to comply with bladder-filling instructions
  • No prior invasive malignancy (except non-melanomatous skin cancer) unless disease-free for a minimum of 3 years
  • No patients with active inflammatory bowel disease
  • No severe, active co-morbidity, defined as follows:
  • Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months
  • Transmural myocardial infarction within the last 6 months
  • Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration
  • Other major medical illness that requires hospitalization or precludes study therapy at the time of registration
  • Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects (however, laboratory test coagulation parameters are not required for entry into this protocol)
  • Acquired Immune Deficiency Syndrome (AIDS) based upon current CDC definition (however, human immunodeficiency virus [HIV] testing is not required for entry into this protocol)

PRIOR CONCURRENT THERAPY:

  • See Disease Characteristics
  • No prior radiation therapy to the pelvis
  • No prior treatment with platinum-based chemotherapy
  • Patients may NOT receive amifostine or other protective reagents

Trial Contact Information

Trial Lead Organizations/Sponsors

Radiation Therapy Oncology Group

National Cancer Institute

Ann KloppPrincipal Investigator

Trial Sites

U.S.A.
Arizona
  Phoenix
 Arizona Oncology - Deer Valley Center
 David G. Brachman Ph: 800-360-6371
  Scottsdale
 Arizona Oncology Services Foundation
 David G. Brachman Ph: 800-360-6371
California
  Fresno
 California Cancer Center - Woodward Park Office
 Uma G Swamy Ph: 559-447-4050
  Oakland
 Kaiser Permanente-Oakland
 Samantha A Seaward Ph: 626-564-3455
  Orange
 St. Joseph Hospital Regional Cancer Center - Orange
 Venita L Williams Ph: 714-734-6220
  Paradise
 Feather River Hospital Cancer Center
 Sam Mazj Ph: 530-876-7995
  Email: haleew@ah.org
  Pomona
 Robert and Beverly Lewis Family Cancer Care Center at Pomona Valley Hospital Medical Center
 Yallapragada S. Rao Ph: 909-865-9555
  Rancho Cardova
 Kaiser Permanente Medical Center - Rancho Cordova
 Samantha A Seaward Ph: 626-564-3455
  Rohnert Park
 Rohnert Park Cancer Center
 Samantha A Seaward Ph: 626-564-3455
  Roseville
 The Permanente Medical Group-Roseville Radiation Oncology
 Samantha A Seaward Ph: 626-564-3455
  Sacramento
 South Sacramento Cancer Center
 Samantha A Seaward Ph: 626-564-3455
 University of California Davis Cancer Center
 Jyoti S Mayadev Ph: 916-734-3089
  Santa Clara
 Kaiser Permanente Medical Center - Santa Clara Homestead Campus
 Samantha A Seaward Ph: 626-564-3455
  South San Francisco
 Kaiser Permanente Cancer Treatment Center
 Samantha A Seaward Ph: 626-564-3455
Colorado
  Aurora
 University of Colorado Cancer Center at UC Health Sciences Center
 Christine M Fisher Ph: 720-848-0650
  Colorado Springs
 Penrose Cancer Center at Penrose Hospital
 Keren Sturtz Ph: 888-785-6789
  Denver
 Porter Adventist Hospital
 Keren Sturtz Ph: 888-785-6789
  Englewood
 Swedish Medical Center
 Keren Sturtz Ph: 888-785-6789
  Littleton
 Rocky Mountain Cancer Centers - Littleton
 Keren Sturtz Ph: 888-785-6789
  Longmont
 Hope Cancer Care Center at Longmont United Hospital
 Keren Sturtz Ph: 888-785-6789
  Loveland
 McKee Medical Center
 Keren Sturtz Ph: 888-785-6789
Delaware
  Newark
 Helen F. Graham Cancer Center at Christiana Hospital
 Adam Raben Ph: 302-733-6227
  Rehoboth Beach
 Beebe Health Campus
 Adam Raben Ph: 302-733-6227
District of Columbia
  Washington
 Washington Cancer Institute at Washington Hospital Center
 Adedamola (Mola) B Omogbehin Ph: 202-877-8839
Florida
  Gainesville
 UF Health Cancer Center
 Anamaria R Yeung Ph: 352-273-8675
  Email: trials@cancer.ufl.edu
  Jacksonville
 University of Florida Health Science Center - Jacksonville
 Anamaria R Yeung Ph: 352-273-8675
  Email: trials@cancer.ufl.edu
  Miami
 Jackson Memorial Hospital
 Lorraine Portelance Ph: 866-574-5124
  Email: Sylvester@emergingmed.com
 University of Miami Sylvester Comprehensive Cancer Center - Miami
 Lorraine Portelance Ph: 866-574-5124
  Email: Sylvester@emergingmed.com
Georgia
  Atlanta
 Georgia Cancer Center for Excellence at Grady Memorial Hospital
 Joseph W Shelton Ph: 404-489-9164
 Northside Hospital Cancer Center
 Sahar E Rosenbaum Ph: 404-303-3355
 Piedmont Hospital
 Adam W Nowlan Ph: 404-425-7943
  Email: ORS@piedmont.org
 Winship Cancer Institute of Emory University
 Joseph W Shelton Ph: 404-489-9164
 Joseph W Shelton Ph: 404-489-9164
  Cumming
 Northside Hospital-Forsyth
 Sahar E Rosenbaum Ph: 404-303-3355
  Savannah
 Nancy N. and J. C. Lewis Cancer and Research Pavilion at St. Joseph's/Candler
 John A Pablo Ph: 800-622-6877
Hawaii
  Ewa Beach
 Leeward Radiation Oncology
 Paul A. DeMare Ph: 808-545-8548
  Honolulu
 Cancer Research Center of Hawaii
 Paul A. DeMare Ph: 808-545-8548
 Hawaii Medical Center - East
 Paul A. DeMare Ph: 808-545-8548
 Queen's Cancer Institute at Queen's Medical Center
 Paul A. DeMare Ph: 808-545-8548
Idaho
  Boise
 Saint Alphonsus Cancer Care Center at Saint Alphonsus Regional Medical Center
 Samir Narayan Ph: 734-712-4673
Illinois
  Chicago
 Creticos Cancer Center at Advocate Illinois Masonic Medical Center
 Paige L Dorn Ph: 773-296-5360
 John H. Stroger, Jr. Hospital of Cook County
 Anupama Thakrar Ph: 312-864-6000
 Robert H. Lurie Comprehensive Cancer Center at Northwestern University
 Eric D Donnelly Ph: 312-695-1301
  Email: cancer@northwestern.edu
 University of Illinois Cancer Center
 Andrew Howard Ph: 312-355-3046
  Harvey
 Ingalls Cancer Care Center at Ingalls Memorial Hospital
 Sulochana D Yalavarthi Ph: 708-915-4673
  Email: clinicaltrials@ingalls.org
Indiana
  Anderson
 Saint John's Health System
 Maria J Valente Ph: 904-538-3667
  Dyer
 Franciscan Saint Margaret Health - Dyer Campus
 Robert D Prock Ph: 708-891-9305
  Fort Wayne
 Radiation Oncology Associates Southwest
 Brian K Chang Ph: 260-373-8888
  Email: parkviewresearch@parkview.com
  Hammond
 Oncology Center at Saint Margaret Mercy Healthcare Center
 Robert D Prock Ph: 708-891-9305
Iowa
  Ames
 McFarland Clinic, PC
 Joseph James Merchant Ph: 515-239-2621
  Clive
 Mercy Cancer Center - West Lakes
 Robert J Behrens Ph: 888-244-6061
  Email: sherrijr@iora.org
  Des Moines
 John Stoddard Cancer Center at Iowa Methodist Medical Center
 Robert J Behrens Ph: 888-244-6061
  Email: sherrijr@iora.org
 Mercy Cancer Center at Mercy Medical Center - Des Moines
 Robert J Behrens Ph: 888-244-6061
  Email: sherrijr@iora.org
Kansas
  Kansas City
 Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center
 Parvesh Kumar Ph: 913-588-4709
Louisiana
  New Orleans
 Ochsner Cancer Institute at Ochsner Clinic Foundation
 Mini J Elnaggar Ph: 888-562-4763
Maryland
  Baltimore
 Greater Baltimore Medical Center Cancer Center
 Geoffrey A Neuner Ph: 443-849-3706
  Salisbury
 Peninsula Regional Medical Center
 Matthew L Snyder Ph: 866-922-6237
Massachusetts
  Boston
 Boston University Cancer Research Center
 Lisa A. Kachnic Ph: 617-638-8265
 Dana-Farber/Brigham and Women's Cancer Center
 Akila Viswanathan Ph: 617-724-5200
 Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute
 Akila Viswanathan Ph: 617-724-5200
  Lowell
 Lowell General Hospital
 Akila Viswanathan Ph: 617-724-5200
  Milford
 Dana-Farber/Brigham and Women's Cancer Center at Milford Regional Medical Center
 Akila Viswanathan Ph: 617-724-5200
  South Weymouth
 Dana-Farber/Brigham and Women's Cancer Center at South Shore
 Akila Viswanathan Ph: 617-724-5200
Michigan
  Ann Arbor
 Saint Joseph Mercy Cancer Center
 Samir Narayan Ph: 734-712-4673
  Detroit
 Van Elslander Cancer Center at St. John Hospital and Medical Center
 Samir Narayan Ph: 734-712-4673
  Grand Rapids
 Butterworth Hospital at Spectrum Health
 Gilbert D Padula Ph: 616-685-5225
 Lacks Cancer Center at Saint Mary's Health Care
 Gilbert D Padula Ph: 616-685-5225
  Warren
 St. John Macomb Hospital
 Samir Narayan Ph: 734-712-4673
Minnesota
  Bemidji
 MeritCare Bemidji
 Preston D. Steen Ph: 701-234-6161
  Saint Paul
 United Hospital
 Paul Sperduto Ph: 952-993-1517
  Email: MMCCOP@parknicollet.com
  Waconia
 Ridgeview Medical Center
 Paul Sperduto Ph: 952-993-1517
  Email: MMCCOP@parknicollet.com
Missouri
  Saint Louis
 David C. Pratt Cancer Center at St. John's Mercy
 Jay W Carlson Ph: 800-821-7532
  Email: sherrijr@iora.org
  Springfield
 Hulston Cancer Center at Cox Medical Center South
 Jay W Carlson Ph: 800-821-7532
  Email: sherrijr@iora.org
 St. John's Regional Health Center
 Jay W Carlson Ph: 800-821-7532
  Email: sherrijr@iora.org
Montana
  Billings
 Billings Clinic Cancer Center - 801 N 29th Street
 Benjamin Thomas Marchello Ph: 800-648-6274
Nebraska
  Omaha
 UNMC Eppley Cancer Center at the University of Nebraska Medical Center
 Andrew O Wahl Ph: 800-999-5465
New Jersey
  Mount Holly
 Virtua Fox Chase Health Cancer Program at Virtua Memorial Hospital Burlington County
 Lemuel S. Ariaratnam Ph: 888-847-8823
  Pennington
 Capital Health Medical Center-Hopewell
 Shirnett Karean Williamson Ph: 800-255-3440
  Voorhees
 Fox Chase Virtua Health Cancer Program at Virtua West Jersey
 Lemuel S. Ariaratnam Ph: 888-847-8823
New Mexico
  Albuquerque
 University of New Mexico Cancer Center
 Thomas M Schroeder Ph: 505-272-6972
New York
  Bay Shore
 Southside Hospital
 Beatrice F Bloom Ph: 516-562-3467
  New Hyde Park
 Long Island Jewish Medical Center
 Beatrice F Bloom Ph: 516-562-3467
 Monter Cancer Center of the North Shore-LIJ Health System
 Beatrice F Bloom Ph: 516-562-3467
  Stony Brook
 Stony Brook University Cancer Center
 Tamara Esther Weiss Ph: 800-862-2215
  Syracuse
 SUNY Upstate Medical University Hospital
 Paul D Aridgides Ph: 315-464-5476
North Carolina
  Charlotte
 Presbyterian Cancer Center at Presbyterian Hospital
 Justin P Favaro Ph: 704-384-5369
  Supply
 South Atlantic Radiation Oncology, LLC
 Michael A Papagikos Ph: 910-251-1839
  Wilmington
 Coastal Carolina Radiation Oncology Center
 Michael A Papagikos Ph: 910-251-1839
North Dakota
  Bismarck
 Medcenter One Hospital Cancer Care Center
 Preston D. Steen Ph: 701-234-6161
  Grand Forks
 Altru Cancer Center at Altru Hospital
 Grant R Seeger Ph: 701-780-6520
Ohio
  Akron
 Summa Center for Cancer Care at Akron City Hospital
 Charles A Kunos Ph: 330-375-6101
  Barberton
 Barberton Citizens Hospital
 Charles A Kunos Ph: 330-375-6101
  Chardon
 Geauga Regional Hospital
 Rodney J Ellis Ph: 800-641-2422
  Cleveland
 Case Comprehensive Cancer Center
 Tracy Sherertz Ph: 800-641-2422
  Columbus
 Zangmeister Center
 J. Philip Kuebler Ph: 800-446-5532
  Medina
 Summa Health Center at Lake Medina
 Charles A Kunos Ph: 330-375-6101
  Mentor
 Lake/University Ireland Cancer Center
 Rodney J Ellis Ph: 800-641-2422
  Middleburg Heights
 Southwest General Health Center
 Rodney J Ellis Ph: 800-641-2422
  Orange Village
 UHHS Chagrin Highlands Medical Center
 Rodney J Ellis Ph: 800-641-2422
  Portsmouth
 Southern Ohio Medical Center Cancer Center
 J. Philip Kuebler Ph: 800-446-5532
  Westlake
 UHHS Westlake Medical Center
 Rodney J Ellis Ph: 800-641-2422
Oklahoma
  Oklahoma City
 Oklahoma University Cancer Institute
 Terence S. Herman Ph: 405-271-4272
  Email: julie-traylor@ouhsc.edu
Pennsylvania
  Paoli
 Cancer Center of Paoli Memorial Hospital
 Albert S DeNittis Ph: 866-225-5654
  State College
 Mount Nittany Medical Center
 Jerome Derdel Ph: 814-231-7813
  Email: smoyer@mountnittany.org
  West Reading
 McGlinn Family Regional Cancer Center at Reading Hospital and Medical Center
 Albert Yuen Ph: 610-988-9323
  Wynnewood
 Lankenau Cancer Center at Lankenau Hospital
 Albert S DeNittis Ph: 866-225-5654
South Carolina
  Charleston
 Hollings Cancer Center at Medical University of South Carolina
 Samuel L Cooper Ph: 843-792-9321
  Greenwood
 Self Regional Cancer Center at Self Regional Medical Center
 Samuel L Cooper Ph: 843-792-9321
South Dakota
  Rapid City
 Rapid City Regional Hospital
 Michael J Swartz Ph: 605-716-3982
  Email: research@rcrh.org
  Sioux Falls
 Sanford Cancer Center at Sanford USD Medical Center
 Miroslaw A Mazurczak Ph: 605-328-1367
Texas
  Dallas
 Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas
 Kevin V Albuquerque Ph: 214-648-7097
  Houston
 Univeristy of Texas M.D. Anderson Cancer Center
 Ann H Klopp Ph: 713-792-3245
  San Antonio
 University of Texas Health Science Center at San Antonio
 Tony Y. Eng Ph: 210-450-3800
  Email: CTO@uthscsa.edu
Utah
  Logan
 Logan Regional Hospital
 R. Jeffrey Lee Ph: 801-507-3950
  Murray
 Jon and Karen Huntsman Cancer Center at Intermountain Medical Center
 R. Jeffrey Lee Ph: 801-507-3950
  Saint George
 Dixie Regional Medical Center - East Campus
 R. Jeffrey Lee Ph: 801-507-3950
  Salt Lake City
 Huntsman Cancer Institute at University of Utah
 David K. Gaffney Ph: 801-581-4477
  Email: clinical.trials@hci.utah.edu
 LDS Hospital
 R. Jeffrey Lee Ph: 801-507-3950
 Utah Cancer Specialists at UCS Cancer Center
 R. Jeffrey Lee Ph: 801-507-3950
Virginia
  Richmond
 Virginia Commonwealth University Massey Cancer Center
 Emma C Fields Ph: 804-628-1939
Washington
  Federal Way
 St. Francis Hospital
 Huong T. Pham Ph: 800-354-9527
  Seattle
 CCOP - Virginia Mason Research Center
 Huong T. Pham Ph: 800-354-9527
West Virginia
  Huntington
 Edwards Comprehensive Cancer Center at Cabell Huntington Hospital
 Maria-Rosalia B. Tria Tirona Ph: 304-399-6617
  Wheeling
 Schiffler Cancer Center at Wheeling Hospital
 Jon David Pollock Ph: 304-243-6442
Wisconsin
  Green Bay
 Vince Lombardi Cancer Clinic - Green Bay at Aurora BayCare Medical Center
 David Carl Rohde Ph: 800-252-2990
  Milwaukee
 Vince Lombardi Cancer Clinic at Aurora St. Luke's Medical Center
 David Carl Rohde Ph: 800-252-2990
  West Allis
 Aurora Women's Pavilion of West Allis Memorial Hospital
 David Carl Rohde Ph: 800-252-2990
Canada
British Columbia
  Kelowna
 British Columbia Cancer Agency - Centre for the Southern Interior
 Francois Bachand Ph: 250-712-3900
  Victoria
 British Columbia Cancer Agency - Vancouver Island Centre
 Caroline L Holloway Ph: 604-877-6010
Ontario
  London
 London Regional Cancer Program at London Health Sciences Centre
 Brian P Yaremko Ph: 519-685-8600
Saskatchewan
  Regina
 Allan Blair Cancer Centre at Pasqua Hospital
 Evgeny Sadikov Ph: 306-766-2213
  Saskatoon
 Saskatoon Cancer Centre at the University of Saskatchewan
 Vijayananda Kundapur Ph: 306-655-2914
Hong Kong
  Chai Wan
 Pamela Youde Nethersole Eastern Hospital
 Amy T Chang Ph: 888-823-5923
  Email: ctsucontact@westat.com
Republic of Singapore
  Singapore
 Cancer Institute at National University Hospital
 Ihsiung J Tang Ph: 888-823-5923
  Email: ctsucontact@westat.com

Link to the current ClinicalTrials.gov record.
NLM Identifer NCT01672892
ClinicalTrials.gov processed this data on October 15, 2014

Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain the same text. Minor changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should be directed to ClinicalTrials.gov.

Back to TopBack to Top